Logo
x

Search

Subscribe Now

ABEC

Insights+ Key Biosimilars Events of March 2021

Insights+ Key Biosimilars Events of March 2021

  • April 1, 2021
mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing Capacity

  • March 23, 2021
Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

    Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

    • May 23, 2023
    BMS and 2seventy bio Report P-III Trial (KarMMa-3) Results of Abecma (idecabtagene vicleucel) for Multiple Myeloma

      BMS and 2seventy bio Report P-III Trial (KarMMa-3) Results of Abecma (idecabtagene vicleucel) for Multiple Myeloma

      • February 13, 2023
      BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

        BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

        • January 21, 2022
        BMS

          BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma

          • August 20, 2021
          Insights+ Key Biosimilars Events of March 2021

            Insights+ Key Biosimilars Events of March 2021

            • April 1, 2021
            BMS and bluebird bio

              BMS and bluebird bio's Abecma (idecabtagene vicleucel) Receive the US FDA's Approval as the First Anti-BCMA CAR T Cell Therapy for...

              • March 29, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.